MDNA - Medicenna gets US patent linked to fusion protein for degenerative diseases

Medicenna Therapeutics (NASDAQ:MDNA) said the U.S. Patent and Trademark Office granted a patent to the company related to composition and methods to treat degenerative diseases via administration of a fusion protein comprising an IL-4 or IL-13 Superkine and an anti-apoptotic Bcl-2 family polypeptide. The U.S. Patent No. 11,352,402 titled, Interleukin-4 Receptor-Binding Fusion Proteins And Uses Thereof, extends into at least 2038, the company said in a June 9 press release. "Anti-apoptotic Bcl-2 proteins are essential to maintain the integrity of mitochondria, which are powerhouses of every cell. This has allowed us to generate novel biologics targeting a broad spectrum of conditions such as autoimmune disorders and neurodegenerative diseases," said Medicenna President and CEO Fahar Merchant.

For further details see:

Medicenna gets US patent linked to fusion protein for degenerative diseases